Table 2. Pharmacokinetic parameters of VP3.15.
| Route | Matrix | Tmax (h) | Cmax (ng.ml−1) | AUClast (h.ng.mL−1) | AUCinf (h.ng.mL−1) | MRTlast (h) | MRTinf (h) |
|---|---|---|---|---|---|---|---|
| VP3.15 | Plasma | 0.25 | 1990.43 | 1956.74 | 1998.55 | 0.82 | 0.91 |
| i.p. | Braina | 0.08 | 1982.38 | 1489.25 | 1506.00 | 1.21 | 1.25 |
| VP3.15 | Plasma | 1.00 | 880.76 | 2292.94 | 2378.17 | 1.64 | 1.86 |
| p.o | Braina | 0.5 | 496.55 | 1375.08 | 1794.28 | 2.07 | 4.01 |
Pharmacokinetic parameters of VP3.15 in plasma and brain following a single intraperitoneal (10 mg.kg−1) and oral (50 mg.kg−1) dose in male BALB/c mice.
aBrain concentration and AUC expressed as ng.g−1 and h.ng.g−1 respectively. MRT: mean residence time.